BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu D, Zhang W, Tang J, Zhou Z, Liu X, Shen Y. Improving safety of cancer immunotherapy via delivery technology. Biomaterials 2021;265:120407. [PMID: 32992118 DOI: 10.1016/j.biomaterials.2020.120407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wei PS, Chen YJ, Lin SY, Chuang KH, Sheu MT, Ho HO. In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR Fab Engager (BiTEE). Biomaterials 2021;278:121166. [PMID: 34634663 DOI: 10.1016/j.biomaterials.2021.121166] [Reference Citation Analysis]
2 Ma B, Bianco A. Recent Advances in 2D Material-Mediated Immuno-Combined Cancer Therapy. Small 2021;:e2102557. [PMID: 34510729 DOI: 10.1002/smll.202102557] [Reference Citation Analysis]
3 Pan S, Li T, Tan Y, Xu H. Selenium-containing nanoparticles synergistically enhance Pemetrexed&NK cell-based chemoimmunotherapy. Biomaterials 2022;280:121321. [PMID: 34922271 DOI: 10.1016/j.biomaterials.2021.121321] [Reference Citation Analysis]
4 Wang J, Zhang Y, Pi J, Xing D, Wang C. Localized delivery of immunotherapeutics: A rising trend in the field. J Control Release 2021;340:149-67. [PMID: 34699871 DOI: 10.1016/j.jconrel.2021.10.013] [Reference Citation Analysis]
5 Tang H, Zhou J, Bai C. The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease. Front Oncol 2021;11:625872. [PMID: 33692958 DOI: 10.3389/fonc.2021.625872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li S, Jiang P, Jiang F, Liu Y. Recent Advances in Nanomaterial‐Based Nanoplatforms for Chemodynamic Cancer Therapy. Adv Funct Mater 2021;31:2100243. [DOI: 10.1002/adfm.202100243] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
7 Kwon M, Jung H, Nam GH, Kim IS. The right Timing, right combination, right sequence, and right delivery for Cancer immunotherapy. J Control Release 2021;331:321-34. [PMID: 33434599 DOI: 10.1016/j.jconrel.2021.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tian Y, Xu C, Feng J, Huangfu Y, Wang K, Zhang ZL. Personalized gel-droplet monocyte vaccines for cancer immunotherapy. Lab Chip 2021;21:4414-26. [PMID: 34676383 DOI: 10.1039/d1lc00646k] [Reference Citation Analysis]
9 Liang JL, Luo GF, Chen WH, Zhang XZ. Recent Advances in Engineered Materials for Immunotherapy-Involved Combination Cancer Therapy. Adv Mater 2021;33:e2007630. [PMID: 34050564 DOI: 10.1002/adma.202007630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]